rkets protein- or other biotechnology-based products known as biosimilars and provides biotechnology manufacturing services to other companies. In Oncology Injectables, Sandoz division develops, manufactures, and markets cytotoxic products for the hospital market. The Sandoz division develops, produces, and markets finished dosage form medicines, as well as intermediary products, including active pharmaceutical ingredients. The Sandoz division’s portfolio primarily includes differentiated products, such as MS treatment Glatopa (glatiramer acetate injection), the cardiovascular polypill Sincronium (acetylsalicylic acid, atorvastatin and ramipril), and the pain medication fentanyl, which is difficult to manufacture because its delivery mechanism is a transdermal patch. Its differentiated products also include biosimilars comprising Omnitrope, a human growth hormone; Binocrit, an erythropoiesis-stimulating agent used to treat anemia; and filgrastim for neutropenia under the brand names Zarzio outside the U.S. and Zarxio in the U.S. In 2015, the Sandoz division’s key product launches in the U.S. included Glatopa, the generic version of Teva's Copaxone 20mg (glatiramer acetate injection); the biosimilar Zarxio (filgrastim-sndz); and budesonide inhalation suspension (Astra Zeneca's Pulmicort Respules), as well as authorized generic versions of the The Medicine Company's Angiomax (bivalirudin); and its Pharmaceutical division's Exelon Patch (rivastigmine patch). In 2015, the Sandoz division’s key product launches in various European countries included aripiprazole TAB (Atsuka's Abilify); duloxetine (Eli Lilly's Cymbalta); pregabalin HGC (Pfizer's Lyrica); and valganciclovir FCT (Roche's Valcyte). In addition, the global rollout of AirFluSal Forspiro continued with launches across Europe. Sales and Marketing The Sandoz division sells a portfolio of generic pharmaceutical products and biosimilars to wholesalers, pharmacies, hospitals, and other healthcare outlets. Its principal markets include the U.S. and Europe. Discontinued Operations Vaccines and Diagnostics division In March 2015, the company completed the divestment of its Vaccines division (excluding its influenza vaccines business) to GSK. In July 2015, the company completed the divestment of its influenza vaccines business to CSL Limited. Consumer Health In January 2015, the company completed the divestment of its Animal Health Division to Eli Lilly and Company. In March 2015, the company completed the divestment of its OTC division, which the company contributed to a new consumer healthcare joint venture with GSK, of which the company owns 36.5%. Significant Events In May 2016, Novartis announced changes to focus its Pharmaceuticals Division by creating two business units reporting to the CEO: Novartis Pharmaceuticals and Novartis Oncology. These business units would form the Innovative Medicines Division at Novartis. The leader of each business would join the Executive Committee of Novartis (ECN) effective July 1, 2016. In June 2016, Xencor, Inc. announced that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb 13676 also expected to begin clinical development for B-cell malignancies in 2016. History Novartis AG was founded in 1895.
novartis ag-sponsored adr (NVS:New York)
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01www.novartis.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for NVS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.